{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T16:25:53Z","timestamp":1759422353853,"version":"3.37.3"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,1,7]],"date-time":"2019-01-07T00:00:00Z","timestamp":1546819200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs - Real World Outcomes"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1007\/s40801-018-0146-9","type":"journal-article","created":{"date-parts":[[2019,1,8]],"date-time":"2019-01-08T15:41:49Z","timestamp":1546962109000},"page":"1-9","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Characterization of Patients with Ankylosing Spondylitis Receiving Secukinumab and Reasons for Initiating Treatment: A US Physician Survey and Retrospective Medical Chart Review"],"prefix":"10.1007","volume":"6","author":[{"given":"Reeti","family":"Joshi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dominick","family":"Latremouille-Viau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark K.","family":"Meiselbach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jipan","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yujin","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prashanth","family":"Sunkureddi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,1,7]]},"reference":[{"key":"146_CR1","doi-asserted-by":"publisher","first-page":"2563","DOI":"10.1056\/NEJMra1406182","volume":"374","author":"JD Taurog","year":"2016","unstructured":"Taurog JD, Chhabra A, Colbert RA. Ankylosing spondylitis and axial spondyloarthritis. N Engl J Med. 2016;374:2563\u201374.","journal-title":"N Engl J Med."},{"key":"146_CR2","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1016\/S0140-6736(07)60635-7","volume":"369","author":"J Braun","year":"2007","unstructured":"Braun J, Sieper J. Ankylosing spondylitis. Lancet. 2007;369:1379\u201390.","journal-title":"Lancet."},{"key":"146_CR3","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1097\/MAJ.0b013e31820f8c99","volume":"341","author":"JD Reveille","year":"2011","unstructured":"Reveille JD. Epidemiology of spondyloarthritis in North America. Am J Med Sci. 2011;341:284\u20136.","journal-title":"Am J Med Sci."},{"key":"146_CR4","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1002\/acr.21621","volume":"64","author":"JD Reveille","year":"2012","unstructured":"Reveille JD, Witter JP, Weisman MH. Prevalence of axial spondylarthritis in the United States: estimates from a cross-sectional survey. Arthritis Care Res (Hoboken). 2012;64:905\u201310.","journal-title":"Arthritis Care Res (Hoboken)."},{"key":"146_CR5","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1097\/MAJ.0b013e318294457f","volume":"345","author":"JD Reveille","year":"2013","unstructured":"Reveille JD, Weisman MH. The epidemiology of back pain, axial spondyloarthritis and HLA-B27 in the United States. Am J Med Sci. 2013;345:431\u20136.","journal-title":"Am J Med Sci."},{"key":"146_CR6","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1002\/art.39298","volume":"68","author":"MM Ward","year":"2016","unstructured":"Ward MM, Deodhar A, Akl EA, et al. American College of Rheumatology\/Spondylitis Association of America\/Spondyloarthritis Research and Treatment Network 2015 recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis. Arthritis Rheumatol. 2016;68:282\u201398.","journal-title":"Arthritis Rheumatol."},{"key":"146_CR7","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1136\/annrheumdis-2016-210770","volume":"76","author":"D Heijde van der","year":"2017","unstructured":"van der Heijde D, Ramiro S, Landewe R, et al. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis. 2017;76:978\u201391.","journal-title":"Ann Rheum Dis."},{"key":"146_CR8","doi-asserted-by":"publisher","first-page":"e000396","DOI":"10.1136\/rmdopen-2016-000396","volume":"3","author":"A Sepriano","year":"2017","unstructured":"Sepriano A, Regel A, van der Heijde D, et al. Efficacy and safety of biological and targeted-synthetic DMARDs: a systematic literature review informing the 2016 update of the ASAS\/EULAR recommendations for the management of axial spondyloarthritis. RMD Open. 2017;3:e000396 (2016-000396, eCollection 2017).","journal-title":"RMD Open."},{"key":"146_CR9","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.semarthrit.2017.04.005","volume":"47","author":"A Deodhar","year":"2017","unstructured":"Deodhar A, Yu D. Switching tumor necrosis factor inhibitors in the treatment of axial spondyloarthritis. Semin Arthritis Rheum. 2017;47:343\u201350.","journal-title":"Semin Arthritis Rheum."},{"key":"146_CR10","doi-asserted-by":"publisher","first-page":"71016-0969-2","DOI":"10.1186\/s13075-016-0969-2","volume":"18","author":"A Ciurea","year":"2016","unstructured":"Ciurea A, Exer P, Weber U, et al. Does the reason for discontinuation of a first TNF inhibitor influence the effectiveness of a second TNF inhibitor in axial spondyloarthritis? Results from the Swiss Clinical Quality Management Cohort. Arthritis Res Ther. 2016;18:71016-0969-2.","journal-title":"Arthritis Res Ther."},{"key":"146_CR11","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1136\/ard.2010.131797","volume":"70","author":"E Lie","year":"2011","unstructured":"Lie E, van der Heijde D, Uhlig T, et al. Effectiveness of switching between TNF inhibitors in ankylosing spondylitis: data from the NOR-DMARD register. Ann Rheum Dis. 2011;70:157\u201363.","journal-title":"Ann Rheum Dis."},{"key":"146_CR12","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1002\/pds.1471","volume":"17","author":"ISPE","year":"2008","unstructured":"ISPE. Guidelines for good pharmacoepidemiology practices (GPP). Pharmacoepidemiol Drug Saf. 2008;17:200\u20138.","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"146_CR13","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.jclinepi.2007.11.008","volume":"61","author":"E Elm von","year":"2008","unstructured":"von Elm E, Altman DG, Egger M, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol. 2008;61:344\u20139.","journal-title":"J Clin Epidemiol."},{"key":"146_CR14","first-page":"1014","volume":"77","author":"M Magrey","year":"2018","unstructured":"Magrey M, Bozyczko M, Wolin D, et al. Treatment experience and satisfaction in ankylosing spondylitis patients treated with secukinumab: results from a US web-based survey [abstract]. Ann Rheum Dis. 2018;77:1014 (SAT0300).","journal-title":"Ann Rheum Dis"},{"key":"146_CR15","first-page":"A1524","volume":"69","author":"KR Oelke","year":"2017","unstructured":"Oelke KR, Garg R, Li Y, et al. Real-world use of secukinumab among biologic-na\u00efve and biologic-experienced patients with ankylosing spondylitis in the United States [abstract]. Arthritis Rheumatol. 2017;69:A1524.","journal-title":"Arthritis Rheumatol."},{"key":"146_CR16","doi-asserted-by":"publisher","first-page":"2534","DOI":"10.1056\/NEJMoa1505066","volume":"373","author":"D Baeten","year":"2015","unstructured":"Baeten D, Sieper J, Braun J, et al. Secukinumab, an interleukin-17A inhibitor, in ankylosing spondylitis. N Engl J Med. 2015;373:2534\u201348.","journal-title":"N Engl J Med."},{"key":"146_CR17","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1136\/annrheumdis-2016-210023","volume":"76","author":"J Sieper","year":"2017","unstructured":"Sieper J, Deodhar A, Marzo-Ortega H, et al. Secukinumab efficacy in anti-TNF-na\u00efve and anti-TNF-experienced subjects with active ankylosing spondylitis: results from the MEASURE 2 Study. Ann Rheum Dis. 2017;76:571\u201392.","journal-title":"Ann Rheum Dis."},{"key":"146_CR18","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1186\/s13075-017-1490-y","volume":"19","author":"K Pavelka","year":"2017","unstructured":"Pavelka K, Kivitz A, Dokoupilova E, et al. Efficacy, safety, and tolerability of secukinumab in patients with active ankylosing spondylitis: a randomized, double-blind phase 3 study, MEASURE 3. Arthritis Res Ther. 2017;19:285.","journal-title":"Arthritis Res Ther."},{"key":"146_CR19","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1111\/bjd.12110","volume":"168","author":"KA Papp","year":"2013","unstructured":"Papp KA, Langley RG, Sigurgeirsson B, et al. Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study. Br J Dermatol. 2013;168:412\u201321.","journal-title":"Br J Dermatol."},{"key":"146_CR20","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1007\/s10067-016-3231-z","volume":"35","author":"A Deodhar","year":"2016","unstructured":"Deodhar A, Mittal M, Reilly P, et al. Ankylosing spondylitis diagnosis in US patients with back pain: identifying providers involved and factors associated with rheumatology referral delay. Clin Rheumatol. 2016;35:1769\u201376.","journal-title":"Clin Rheumatol."},{"key":"146_CR21","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1007\/s10067-015-2958-2","volume":"34","author":"A Danve","year":"2015","unstructured":"Danve A, Deodhar A. Screening and referral for axial spondyloarthritis\u2014need of the hour. Clin Rheumatol. 2015;34:987\u201393.","journal-title":"Clin Rheumatol."},{"key":"146_CR22","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1007\/s10067-018-4112-4","volume":"37","author":"C L\u00f3pez-Medina","year":"2018","unstructured":"L\u00f3pez-Medina C, Garrido-Castro JL, Castro-Jim\u00e9nez J, et al. Evaluation of quality of life in patients with axial spondyloarthritis and its association with disease activity, functionality, mobility, and structural damage. Clin Rheumatol. 2018;37:1581\u20138.","journal-title":"Clin Rheumatol."}],"container-title":["Drugs - Real World Outcomes"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40801-018-0146-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40801-018-0146-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40801-018-0146-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,1,6]],"date-time":"2020-01-06T19:14:23Z","timestamp":1578338063000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40801-018-0146-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,7]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["146"],"URL":"https:\/\/doi.org\/10.1007\/s40801-018-0146-9","relation":{},"ISSN":["2199-1154","2198-9788"],"issn-type":[{"type":"print","value":"2199-1154"},{"type":"electronic","value":"2198-9788"}],"subject":[],"published":{"date-parts":[[2019,1,7]]},"assertion":[{"value":"7 January 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"This study was sponsored by Novartis Pharmaceuticals Corporation, East Hanover, NJ.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"R. Joshi has received consulting fees from Novartis. D. Latremouille-Viau, M. K. Meiselbach, and J. Xie are employees of Analysis Group, Inc. Y. Park is an employee of Novartis Pharmaceuticals Corporation. P. Sunkureddi has received consulting and speakers\u2019 bureau fees from Novartis, and is an investigator of a clinical trial sponsored by Novartis.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"An institutional review board exemption was obtained for the study prior to initiation of data collection.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human participants"}},{"value":"Informed consent was not required in this study because the data collected did not contain personal identifiers.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}